Pyruvate Kinase Pklr

Introduction

Pyruvate kinase is a key enzyme in cellular metabolism, playing a critical role in glycolysis, the metabolic pathway that converts glucose into pyruvate to generate energy in the form of ATP. The genePKLR(Pyruvate Kinase Liver and Red Blood Cell) encodes two distinct isoforms of this enzyme: the L-type, predominantly found in the liver, kidney, and pancreatic β-cells, and the R-type, specific to red blood cells.

Biological Basis

Biologically, pyruvate kinase catalyzes the final step of glycolysis, transferring a phosphate group from phosphoenolpyruvate (PEP) to adenosine diphosphate (ADP), yielding pyruvate and adenosine triphosphate (ATP). This reaction is irreversible under physiological conditions and is a major regulatory point in glucose metabolism. The different isoforms encoded byPKLRare adapted to the specific metabolic demands of their respective tissues. For instance, the liver L-type isoform is subject to complex hormonal regulation, responding to changes in glucose levels to manage glucose storage and release. The red blood cell R-type isoform is crucial for maintaining ATP levels necessary for erythrocyte function and survival.

Clinical Relevance

Genetic variations within the PKLR gene can have significant clinical implications. Mutations in PKLRare a primary cause of pyruvate kinase deficiency, an autosomal recessive inherited disorder that predominantly affects red blood cells. This deficiency leads to chronic non-spherocytic hemolytic anemia, characterized by the premature destruction of red blood cells due to insufficient ATP production, impacting cellular integrity and function. Beyond rare monogenic disorders, common genetic variants in genes encoding metabolic enzymes, likePKLR, are increasingly being studied for their influence on various metabolic traits. Genome-wide association studies (GWAS) have identified numerous genetic loci that affect plasma levels of liver enzymes ^[1]and impact diverse metabolite profiles in human serum, including sugars, amino acids, and lipids.^[2] Understanding how variants in PKLR might influence these broader metabolic phenotypes could shed light on individual susceptibility to conditions affecting liver function or overall metabolic health.

Social Importance

The social importance of studying genes like PKLRlies in its contribution to both rare disease diagnosis and the broader understanding of metabolic health. For individuals with pyruvate kinase deficiency, accurate genetic diagnosis throughPKLR sequencing is crucial for appropriate clinical management and genetic counseling. Furthermore, as research uncovers the role of genetic variations in common metabolic traits, insights into PKLRcan contribute to a more personalized approach to health. Understanding how genetic predispositions influence liver enzyme levels or metabolite profiles can inform risk assessments for conditions such as non-alcoholic fatty liver disease (NAFLD) or other metabolic disorders. This knowledge may eventually facilitate the development of targeted preventive strategies or therapies, improving public health outcomes related to metabolic well-being.

Limitations

Methodological and Statistical Power Constraints

The interpretation of genetic associations, including those potentially involving pyruvate kinase pklr, is often constrained by the inherent study design and statistical considerations of genome-wide association studies (GWAS). Many studies, particularly those with moderate cohort sizes, face limitations in statistical power, increasing the susceptibility to false negative findings and hindering the detection of genetic associations with modest effect sizes. ^[3] Conversely, the extensive multiple testing performed in GWAS elevates the risk of false positive findings, necessitating stringent statistical thresholds and robust validation. ^[3] This underscores the critical importance of independent replication in diverse cohorts to confirm initial discoveries and differentiate true genetic signals from chance associations. ^[3]

Furthermore, the scope of genetic variation surveyed in some GWAS is limited, as they may utilize a subset of available single nucleotide polymorphisms (SNPs) or older genotyping platforms.^[4] This incomplete coverage of the genome means that causal variants or important genes not directly represented on the SNP array could be missed, impacting the comprehensive understanding of a trait’s genetic architecture. ^[5] The identified SNPs often serve as proxies for ungenotyped functional variants, requiring extensive follow-up to fine-map and identify the true underlying biological mechanisms. ^[6]

Generalizability and Phenotypic Measurement Challenges

A notable limitation in the broader applicability of GWAS findings relates to the generalizability of study populations. Many investigations are conducted primarily in cohorts of white European ancestry, which restricts the direct translation of results to other ethnic groups and diverse populations. ^[7] This lack of ethnic diversity makes it challenging to ascertain whether identified associations for traits like pyruvate kinase pklr would hold true, differ, or even be present in populations with different genetic backgrounds and environmental exposures. ^[7]

Challenges in accurate and consistent phenotypic measurement also impact the reliability and comparability of results. For instance, reliance on surrogate markers or specific measurement methods, such as using TSH as a sole indicator of thyroid function due to the absence of free thyroxine data, can introduce caveats in interpretation.^[7] Additionally, the statistical handling of non-normally distributed quantitative traits, which often requires complex transformations, can affect the power to detect associations and the straightforward interpretation of effect sizes. ^[8] The possibility of sex-specific or context-dependent genetic effects further complicates analyses, as these may remain undetected in pooled or undifferentiated study designs. ^[4]

Environmental Confounders and Remaining Knowledge Gaps

The intricate interplay between genetic predispositions and environmental factors represents a significant, yet often underexplored, limitation in understanding complex traits. Many studies acknowledge the potential for genetic variants to influence phenotypes in a context-specific manner, where environmental exposures—such as diet or lifestyle—can modulate genetic effects.^[4] However, comprehensive investigations of these gene-environment interactions are frequently omitted, leaving a critical gap in our understanding of how these factors collectively contribute to a trait. ^[4]

This omission, alongside the non-identification of all causal genetic variants and potential epistatic interactions, contributes to the phenomenon of “missing heritability”. ^[9] Even with significant GWAS findings, the identified loci often explain only a fraction of the total phenotypic variance for complex traits. This suggests that a substantial portion of genetic influence, including the roles of rare variants, structural variations, and complex gene-gene or gene-environment interactions, remains to be elucidated. ^[9] Future research for traits like pyruvate kinase pklr must therefore integrate multi-omics data and sophisticated analytical frameworks to uncover these presently hidden genetic and environmental contributions.

Variants

Genetic variations play a crucial role in shaping individual metabolic profiles and disease susceptibility, often influencing key enzymatic pathways like glycolysis, where pyruvate kinase liver and red blood cell type (PKLR) is central. Variants within the PKLR gene itself, such as rs113403872 , rs115736167 , and rs61755431 , can directly impact the efficiency of pyruvate kinase, an enzyme vital for the final step of glycolysis, converting phosphoenolpyruvate to pyruvate. Alterations inPKLRactivity can affect glucose metabolism, energy production in red blood cells, and lipid synthesis in the liver, contributing to conditions like pyruvate kinase deficiency or influencing susceptibility to metabolic disorders.^[8]These single nucleotide polymorphisms (SNPs) may affect the enzyme’s expression levels or catalytic efficiency, with broad consequences for cellular energy homeostasis.^[2] Furthermore, the intergenic variant rs141119689 , located near both PKLR and FDPS (Farnesyl Diphosphate Synthase), suggests a regulatory interplay between glycolysis and the mevalonate pathway. FDPSis a key enzyme in cholesterol synthesis, and a variant affecting both genes could indicate a shared regulatory mechanism influencing the interconnected processes of carbohydrate and lipid metabolism.

Other variants influence genes that act as fundamental regulators of gene expression and cellular function, with potential indirect impacts on PKLR and related metabolic processes. For example, IKZF1 (IKAROS Family Zinc Finger 1) encodes a transcription factor critical for lymphocyte development, and its variant rs6592965 may alter its regulatory capacity, potentially affecting cell differentiation and the metabolic demands of specific cell types. Similarly, SOX6 (SRY-Box Transcription Factor 6), another transcription factor involved in development and cellular differentiation, can have its function modified by variants like rs11023895 , thereby influencing the expression of numerous downstream genes, including those involved in metabolic pathways. ^[10] The ASH1L (ASH1 Like Histone Lysine Methyltransferase) gene, with its variant rs528251553 , is an epigenetic regulator involved in histone methylation, which directly controls gene transcription. Variations in ASH1Lcan lead to widespread changes in gene expression patterns, potentially altering the metabolic state of cells and indirectly affecting enzymes like pyruvate kinase by modifying the epigenetic landscape around metabolic genes.^[8]

Variants affecting genes involved in protein synthesis and cellular energy signaling also contribute to the complex regulation of metabolism. EIF4A3 (Eukaryotic Translation Initiation Factor 4A3) is a core component of the exon junction complex, essential for proper mRNA processing and efficient protein synthesis, and its variant rs2361710 could modulate overall protein production rates, including that of metabolic enzymes. Likewise, HBS1L (HBS1 Like Translational GTPase) plays a role in translation termination and ribosome recycling, with its variant rs11759553 potentially influencing the efficiency of protein synthesis and cellular stress responses that impact energy metabolism. ^[1] Furthermore, ENTREP3 (rs41264929 ) and SARM1 (Sterile Alpha And TIR Motif Containing 1, rs967645 ) represent genes involved in broader cellular processes, such as potential transport or signaling functions for ENTREP3, and critical NAD+ metabolism for SARM1. Variations in these genes can alter cellular energy status or signaling pathways, which in turn can fine-tune the activity and expression of metabolic enzymes like PKLR to maintain cellular homeostasis. ^[2]

Key Variants

RS ID	Gene	Related Traits
rs113403872 rs115736167 rs61755431	PKLR	erythrocyte count hemoglobin measurement hematocrit pyruvate kinase pklr measurement
rs6592965	IKZF1	erythrocyte volume erythrocyte count mean corpuscular hemoglobin reticulocyte count platelet count
rs2361710	EIF4A3	reticulocyte count HMBS/PKLR protein level ratio in blood ARG1/PKLR protein level ratio in blood BLVRB/PKLR protein level ratio in blood PKLR/PSMD9 protein level ratio in blood
rs11023895	SOX6	Red cell distribution width pyruvate kinase pklr measurement
rs41264929	ENTREP3	level of disintegrin and metalloproteinase domain-containing protein 15 in blood pyruvate kinase pklr measurement
rs528251553	ASH1L	pyruvate kinase pklr measurement
rs11759553	HBS1L	NSFL1C/STIP1 protein level ratio in blood PSME2/PSMG3 protein level ratio in blood PSMD9/UBAC1 protein level ratio in blood platelet count level of alpha-hemoglobin-stabilizing protein in blood
rs141119689	PKLR - FDPS	reticulocyte count pyruvate kinase pklr measurement phosphoglyceric acid measurement phosphoenolpyruvic acid measurement
rs967645	SARM1	blood protein amount free cholesterol measurement, high density lipoprotein cholesterol measurement cholesteryl ester measurement, high density lipoprotein cholesterol measurement lipid measurement, high density lipoprotein cholesterol measurement filamin-A measurement

Signs and Symptoms for ‘pyruvate kinase pklr’

Metabolic Dysregulation and Diabetes Susceptibility

Variants affecting the _GCKR_(Glucokinase Regulatory Protein) gene are associated with significant dysregulation of glucose metabolism, presenting as defects in the sensitivity of beta cells to glucose.^[11]This metabolic imbalance leads to reduced glucose phosphorylation and impaired hepatic storage of glucose as glycogen.^[11]Clinically, these presentations are characteristic of a susceptibility-gene candidate for Maturity-Onset Diabetes of the Young type 2 (MODY-2, MIM 606391), a form of non-insulin-dependent diabetes with an autosomal-dominant inheritance pattern.^[11]The typical age of onset for MODY-2 is young, generally before 25 years of age, and is primarily characterized by defects in insulin secretion.^[11]

Biochemical Markers and Diagnostic Assessment

The metabolic consequences of _GCKR_ polymorphisms can be assessed through various objective and subjective measures. Elevated fasting serum triacylglycerol levels are a key objective biomarker. ^[11]Furthermore, reduced fasting and Oral Glucose Tolerance Test (OGTT)-related insulinaemia indicate impaired insulin response.^[11] Comprehensive metabolomics, which involves the measurement of endogenous metabolites such as lipids, carbohydrates, and amino acids in bodily fluids, serves as a functional readout of the physiological state and can reveal metabolic phenotypes induced by genetic variants. ^[2] Functional analyses of human _GCK_gene mutations can further explore the regulatory mechanisms of glucokinase activity, providing insights into the molecular basis of these presentations.^[12]

Phenotypic Variability and Clinical Implications

The clinical presentation and severity associated with _GCKR_ variants can exhibit inter-individual variability, particularly in the context of complex metabolic traits. ^[2]While MODY-2 typically presents with an early age of onset, the specific patterns of reduced glucose phosphorylation and hepatic glycogen storage may vary among affected individuals.^[11] Genetic variants influencing pathways related to key lipids, carbohydrates, or amino acids can lead to distinct metabolic footprints, highlighting the phenotypic diversity. ^[2] The diagnostic significance of _GCKR_polymorphisms extends to identifying individuals at reduced risk of type 2 diabetes, even while predisposing to other forms of glucose dysregulation like MODY-2.^[11]

Biological Background

Metabolic Pathways and Regulation

The human body relies on intricately regulated metabolic pathways to maintain energy homeostasis and cellular function. Key enzymes catalyze reactions vital for the synthesis and breakdown of essential biomolecules, with disruptions often leading to disease. For instance, theHMGCR enzyme is a critical component of the mevalonate pathway, which is central to cholesterol synthesis. ^[6] Similarly, the GCKRprotein functions as a regulatory agent, inhibiting glucokinase in both liver and pancreatic-islet cells, thereby influencing glucose phosphorylation and the liver’s capacity for glucose storage.^[11] Beyond these, the PNPLA3 protein, expressed in the liver, exhibits phospholipase activity and plays a dual role in facilitating both energy mobilization and lipid storage within adipose tissue and the liver, with its mRNA expression shown to be elevated in obese individuals. ^[1]

Lipid metabolism is a particularly complex area involving various proteins and enzymes. For example, PCSK9accelerates the degradation of the low-density lipoprotein receptor (LDLR), a process essential for maintaining healthy cholesterol levels. ^[13] Genetic variations in genes like MLXIPLare strongly associated with plasma triglyceride levels, while theFADS gene cluster is linked to the composition of polyunsaturated fatty acids. ^[2] The enzyme LIPC also plays a role in influencing phospholipid levels, highlighting the extensive enzymatic network governing lipid profiles. ^[2] Furthermore, the burgeoning field of metabolomics provides a functional readout of the physiological state by comprehensively measuring endogenous metabolites such as lipids, carbohydrates, and amino acids. ^[2]

Genetic Influences on Gene and Protein Expression

Genetic mechanisms profoundly influence metabolic phenotypes by regulating gene and protein expression. The central dogma of molecular genetics posits that DNA is transcribed into RNA, which is then translated into proteins, with alterations at any of these levels potentially affecting human health. ^[8] Genome-wide association studies (GWAS) have revealed many DNA variants that impact mRNA expression levels, known as expression quantitative trait loci (eQTLs), and also protein levels, termed protein quantitative trait loci (pQTLs). ^[8] For example, variations in the PNPLA3gene include nonsynonymous single nucleotide polymorphisms (SNPs) that are thought to act as exonic splicing silencer elements, potentially influencing gene regulation.^[1]

Alternative splicing is another critical genetic regulatory mechanism, demonstrated by common SNPs in HMGCR that affect the alternative splicing of exon 13, impacting the enzyme’s activity and ultimately LDL-cholesterol levels. ^[6] The regulation of protein abundance can also occur through diverse mechanisms, including altered transcription rates, such as observed for GGT1, or post-translational processes like the cleavage rates of soluble receptors, exemplified by IL6R. ^[8]These genetic variations contribute to the subtle differences in gene and protein expression that underlie individual variations in metabolic traits and disease susceptibility, serving as intermediate phenotypes to bridge genetic variation with complex diseases.^[2]

Cellular Signaling and Inter-Organ Communication

Cellular signaling pathways and the communication between different organs are fundamental to systemic metabolic control. Hormones and their corresponding receptors mediate many of these interactions, integrating diverse physiological signals. For instance, the thyroid hormone receptor interacts with specific proteins, with these interactions being dependent on the presence or absence of thyroid hormone, illustrating a key regulatory mechanism.^[14] Receptors like LEPR(leptin receptor) andIL6R (interleukin 6 receptor) are recognized components of metabolic-syndrome pathways, playing roles in broader systemic responses. ^[8] The level of circulating proteins, such as those associated with IL6R, can be influenced by altered cleavage rates of bound to unbound soluble receptor, affecting overall signaling dynamics. ^[8]

Cellular processes also contribute to inter-organ communication and metabolic regulation. The ubiquitination pathway, for example, is critical for protein degradation, with PARK2 functioning as a ubiquitin ligase involved in this process. ^[2] Such degradation pathways ensure proper protein turnover and regulate the availability of key metabolic components. Another protein, PLEK, is known to associate with plasma membranes and induce membrane projections, suggesting its role in cellular structure and potentially in signal transduction at the cell surface. ^[2] These molecular and cellular events collectively orchestrate the complex communication network necessary for maintaining metabolic balance across tissues and organs.

Pathophysiological Processes and Disease Relevance

Disruptions in metabolic homeostasis often lead to a range of pathophysiological processes, including metabolic disorders and cardiovascular diseases. Nonalcoholic fatty liver disease (NAFLD) is one such condition, where glycosylphosphatidylinositol-specific phospholipase D has been investigated for its role.^[15]Plasma levels of liver enzymes, such as alanine aminotransferase (ALT) and alkaline phosphatase, are important biomarkers, with genetic variants, including those nearPNPLA3, associated with elevated ALT levels and an increased risk for NAFLD. ^[1] Dyslipidemia, characterized by abnormal lipid levels, is another common metabolic disorder, with numerous genetic loci, including PCSK9, MLXIPL, APOA5, and GCKR, contributing to its polygenic nature and influencing traits like LDL-cholesterol and triglyceride levels.^[13]

Metabolic dysregulation can also manifest as type 2 diabetes and related conditions. The GCKRgene, by regulating glucokinase, impacts the sensitivity of beta cells to glucose and hepatic glucose storage, and mutations in this gene can result in defects associated with maturity-onset diabetes of the young (MODY-2).^[11] Similarly, the hepatic nuclear factor 1-alpha, encoded by HNF1A, is functionally linked to another form of diabetes, MODY-3, which is characterized by primary defects in insulin secretion.^[11]The identification of genetic variants influencing these metabolic and enzymatic pathways provides crucial insights into the underlying mechanisms of common human diseases, allowing for a better understanding of disease risk and potential therapeutic targets.^[8]

Pathways and Mechanisms

Regulation of Core Metabolic Pathways and Energy Homeostasis

Genetic variations exert significant influence over fundamental metabolic pathways, impacting the homeostasis of key lipids, carbohydrates, and amino acids. Studies have identified loci affecting plasma levels of liver enzymes, such as those within the CPN1-ERLIN1-CHUK and PNPLA3-SAMM50 regions, highlighting their role in metabolic regulation relevant to liver function. ^[1] The mevalonate pathway, crucial for cholesterol biosynthesis, is subject to complex regulation, exemplified by variations in HMGCR that influence LDL-cholesterol levels and involve alternative splicing mechanisms. ^[6] These metabolic insights, often derived from genome-wide association studies and metabolomics, reveal how genetic predispositions contribute to individual metabolic phenotypes and can serve as intermediate phenotypes for complex diseases. ^[2]

Further metabolic control is evident in glucose and uric acid processing. A polymorphism inGCKRis associated with altered fasting serum triacylglycerol, insulinemia, and type 2 diabetes risk, primarily by modulating glucokinase activity.^[12] Similarly, the SLC2A9 (GLUT9) gene plays a critical role as a renal urate anion exchanger, influencing serum uric acid concentrations and contributing to conditions like gout.^[16] Lipid metabolism is also profoundly affected by genetic factors, with variations in the FADSgene cluster impacting polyunsaturated fatty acid composition andMLXIPLaffecting plasma triglyceride levels.^[17] The enzyme LIPC, involved in phospholipid metabolism, also shows associations with type 2 diabetes and other complex disorders, suggesting broad implications of lipid pathway regulation. ^[2]

Orchestration of Gene Expression and Protein Function

Regulatory mechanisms influencing gene expression and protein activity are diverse and tightly controlled, often involving intricate signaling cascades. Transcription factor regulation, such as the synergistic trans-activation of the human C-reactive protein promoter by HNF-1, illustrates how specific DNA-binding proteins control gene transcription in response to physiological cues. ^[18]Furthermore, interactions between proteins and hormone receptors, like those with the thyroid hormone receptor, represent a class of regulatory mechanisms that modulate gene expression based on hormonal signals.^[14] The precise control of protein variants through alternative pre-mRNA splicing, as observed for HMGCRexon13, adds another layer of regulatory complexity that can alter protein function and contribute to human disease.^[6]

Post-translational modifications and protein stability are equally vital for functional regulation. The ubiquitin ligase PARK2(parkin) is critical for protein degradation pathways, and its dysfunction can lead to conditions like Parkinson’s disease, highlighting the importance of proteolytic control.^[2] Other modifications, such as phosphorylation, are exemplified by PLEK, where phosphorylation is necessary for its association with plasma membranes and subsequent induction of membrane projections. ^[19] Moreover, the oligomerization state of enzymes like 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) can influence their degradation rates, providing a dynamic mechanism for adjusting enzyme levels and activity. ^[20]

Interconnected Signaling and Metabolic Crosstalk

Biological pathways rarely operate in isolation; instead, they form intricate networks of crosstalk and hierarchical regulation that collectively determine cellular and organismal physiology. Genetic variants within genes such as LEPR, HNF1A, IL6R, and GCKR have been found to associate with plasma C-reactive protein, demonstrating how distinct metabolic, inflammatory, and signaling pathways converge to influence systemic biomarkers. ^[11]For instance, leptin receptor (LEPR) variability impacts plasma fibrinogen levels, indicating a link between satiety signaling and coagulation pathways. ^[21]The interplay between glucose and lipid metabolism is underscored by the dual impact ofGCKRon both triglyceride levels and insulin sensitivity.^[22]

These network interactions are crucial for maintaining systemic homeostasis and can manifest as distinct metabolic phenotypes in individuals. ^[23] The impact of PARK2on amino acid interconversion suggests a broader role for ubiquitin ligases in metabolic pathway integration beyond protein degradation.^[2] Furthermore, comprehensive studies exploring intermediate phenotypes through metabolomics reveal how genetic variations, like those affecting phospholipids via LIPC, can link to a spectrum of complex diseases, including type 2 diabetes, bipolar disorder, and rheumatoid arthritis, underscoring the emergent properties of interconnected biological systems.^[2]

Disease Relevance and Therapeutic Implications

The dysregulation of metabolic and signaling pathways is a hallmark of numerous human diseases, making these pathways critical targets for diagnostic and therapeutic interventions. Genetic variants in genes associated with lipid metabolism, such as HMGCR and the FADScluster, contribute to dyslipidemia and cardiovascular disease risk.^[6] Similarly, variations in SLC2A9directly impact uric acid levels and are associated with the pathogenesis of gout.^[24] The recognition that plasma liver enzyme levels are influenced by genetic variation, including loci like CPN1-ERLIN1-CHUK and PNPLA3-SAMM50, provides a genetic basis for liver diseases and offers insights for monitoring drug treatment. ^[1]

Understanding these mechanisms at a molecular level is crucial for identifying therapeutic targets and developing personalized medicine approaches. For example, the genetic basis of type 2 diabetes is partially illuminated by variants in GCKR and LEPR, which influence glucose and lipid metabolism, respectively.^[11]Insights from metabolomics, which captures the functional readout of the physiological state, further bridge the gap between genetic variants and disease mechanisms by identifying intermediate metabolic phenotypes that can predict or indicate disease susceptibility.^[2] The identification of ubiquitin ligases like PARK2 in neurodegenerative diseases illustrates how fundamental cellular processes, when dysregulated, can lead to severe pathologies. ^[2]

References

[1] Yuan X, et al. “Population-based genome-wide association studies reveal six loci influencing plasma levels of liver enzymes.” Am J Hum Genet, vol. 83, no. 4, 2008, pp. 521–529.

[2] Gieger C, et al. “Genetics meets metabolomics: a genome-wide association study of metabolite profiles in human serum.”PLoS Genet, vol. 4, no. 11, 2008, e1000282.

[3] Benjamin, Emelia J. “Genome-wide association with select biomarker traits in the Framingham Heart Study.” BMC Medical Genetics, 2007. PMID: 17903293.

[4] Vasan, Ramachandran S. “Genome-wide association of echocardiographic dimensions, brachial artery endothelial function and treadmill exercise responses in the Framingham Heart Study.”BMC Medical Genetics, 2007. PMID: 17903301.

[5] Yang, Qiong. “Genome-wide association and linkage analyses of hemostatic factors and hematological phenotypes in the Framingham Heart Study.”BMC Medical Genetics, 2007. PMID: 17903294.

[6] Burkhardt, R., et al. “Common SNPs in HMGCR in micronesians and whites associated with LDL-cholesterol levels affect alternative splicing of exon13.” Arterioscler Thromb Vasc Biol, 2009.

[7] Hwang, Shih-Jen. “A genome-wide association for kidney function and endocrine-related traits in the NHLBI’s Framingham Heart Study.” BMC Medical Genetics, 2007. PMID: 17903292.

[8] Melzer D, et al. “A genome-wide association study identifies protein quantitative trait loci (pQTLs).” PLoS Genet, 2008.

[9] Sabatti, Chiara. “Genome-wide association analysis of metabolic traits in a birth cohort from a founder population.”Nature Genetics, 2008. PMID: 19060910.

[10] Saxena R, et al. “Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels.” Science, 2007.

[11] Ridker, P. M., et al. “Loci related to metabolic-syndrome pathways including LEPR,HNF1A, IL6R, and GCKR associate with plasma C-reactive protein: the Women’s Genome Health Study.”Am J Hum Genet, 2008.

[12] Garcia-Herrero, C.M., et al. “Functional analysis of human glucokinase gene mutations causing MODY2: exploring the regulatory mechanisms of glucokinase activity.”Diabetologia, vol. 50, 2007, pp. 325–333.

[13] Kathiresan, S., et al. “Common variants at 30 loci contribute to polygenic dyslipidemia.” Nat Genet, 2008.

[14] Lee, J. W., et al. “Two classes of proteins dependent on either the pres- ence or absence of thyroid hormone for interaction with the thyroid hormone receptor.”Mol. Endocrinol., 1995.

[15] Chalasani, N., et al. “Glycosylphosphatidylinositol-specific phospholipase d in nonalcoholic Fatty liver disease: A preliminary study.”J. Clin. Endocrinol. Metab., 2006.

[16] Döring, Angela, et al. “SLC2A9 Influences Uric Acid Concentrations With Pronounced Sex-Specific Effects.”Nature Genetics, vol. 40, 2008, pp. 430-436.

[17] Kooner, J. S., et al. “Genome-wide scan identifies variation in MLXIPL associated with plasma triglycerides.” Nat Genet, 2008.

[18] Toniatti, Carlo, et al. “Synergistic Trans-Activation of the Human C-Reactive Protein Promoter by Transcription Factor HNF-1 Binding at Two Distinct Sites.”The EMBO Journal, vol. 9, 1990, pp. 4467-4475.

[19] Ma, Allan D., et al. “Pleckstrin Associates With Plasma Membranes and Induces the Formation of Membrane Projections: Requirements for Phosphorylation and the NH2-Terminal PH Domain.” Journal of Cell Biology, vol. 136, 1997, pp. 1071-1079.

[20] Cheng, Hwa H., et al. “Oligomerization State Influences the Degradation Rate of 3-Hydroxy-3-Methylglutaryl-CoA Reductase.” Journal of Biological Chemistry, vol. 274, 1999, pp. 17171-17178.

[21] Zhang, Yan Y., et al. “Genetic Variability at the Leptin Receptor (LEPR) Locus Is a Determinant of Plasma Fibrinogen.”Journal of Clinical Endocrinology & Metabolism, vol. 92, 2007, pp. 3217-3222.

[22] Sparso, Torben, et al. “The GCKR rs780094 Polymorphism Is Associated With Elevated Fasting Serum Triacylglycerol, Reduced Fasting and OGTT-Related Insulinaemia, and Reduced Risk of Type 2 Diabetes.” Diabetologia, vol. 51, 2008, pp. 70-75.

[23] Assfalg, Michael, et al. “Evidence of Different Metabolic Phenotypes in Humans.” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, 2008, pp. 1420-1424.

[24] Vitart, Veronique, et al. “SLC2A9 Is a Newly Identified Urate Transporter Influencing Serum Urate Concentration, Urate Excretion and Gout.”Nature Genetics, vol. 40, 2008, pp. 437-442.